請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34284
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賈景山 | |
dc.contributor.author | Hsueh-Ju Chen | en |
dc.contributor.author | 陳學儒 | zh_TW |
dc.date.accessioned | 2021-06-13T06:01:20Z | - |
dc.date.available | 2016-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-26 | |
dc.identifier.citation | Ajdic, D., McShan, W.M., McLaughlin, R.E., Savic, G., Chang, J., Carson, M.B., Primeaux, C., Tian, R.Y., Kenton, S., Jia, H.G.(2002). Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. P. Natl. Acad. Sci. USA 99, 14434-14439.
Archer, G.L., Vazquez, G.J., and Johnston, J.L. (1980). Antibiotic-prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. J. Infect. Dis. 142, 725-731. Baker, C.N., and Thornsberry, C. (1974). Antimicrobial susceptibility of Streptococcus mutans isolated from patients with endocarditis. Antimicrob. Agents. Chemother. 5, 268-271. Beachey, E.H., and Stollerman, G.H. (1971). Toxic effects of streptococcal M protein on platelets and polymorphonuclear leukocytes in human blood. J. Exp. Med. 134, 351-365. Bensing, B.A., Lopez, J.A., and Sullam, P.M. (2004). The Streptococcus gordonii surface proteins GspB and Hsa mediate binding to sialylated carbohydrate epitopes on the platelet membrane glycoprotein Ibalpha. Infect. Immun. 72, 6528-6537. Briheim, G., and Dahlgren, C. (1987). Influence of antibiotics on formylmethionyl-leucyl-phenylalanine-induced leukocyte chemiluminescence. Antimicrob. Agents. Chemother. 31, 763-767. Burroughs, S.F., and Johnson, G.J. (1990). Beta-lactam antibiotic-induced platelet dysfunction: evidence for irreversible inhibition of platelet activation in vitro and in vivo after prolonged exposure to penicillin. Blood 75, 1473-1480. Cosimelli, M., Tedesco, M., Giannarelli, D., Cavaliere, F., Mannella, E., Botti, C., Tamburelli, A., Minasi, P., and Cavaliere, R. (1993). The role of the administration time of prophylactic antibiotic therapy in colorectal cancer surgery: a review of 6,069 patients from 36 randomized clinical trials. Ann. Ital. Chir. 64, 527-532. de Jager, C.P., van Wijk, P.T., Mathoera, R.B., de Jongh-Leuvenink, J., van der Poll, T., and Wever, P.C. (2010). Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit. Care. 14, R192. Dejonckheere, M., Levarlet, M., and D'Hollander, A. (1993). Intramuscular buprenorphine for pain relief after abdominal surgery: a comparison between on-demand and prophylactic administration. Eur. J. Anaesthesiol. 10, 291-295. Dhawan, V.K., Bayer, A.S., and Yeaman, M.R. (2000). Thrombin-induced platelet microbicidal protein susceptibility phenotype influences the outcome of oxacillin prophylaxis and therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents. Chemother. 44, 3206-3209. DiPiro, J.T., Adkinson, N.F., Jr., and Hamilton, R.G. (1993). Facilitation of penicillin haptenation to serum proteins. Antimicrob. Agents. Chemother. 37, 1463-1467. du Vigneaud, V., Carpenter, F.H., Holley, R.W., Livermore, A.H., and Rachele, J.R. (1946). Synthetic penicillin. Science 104, 431-450. Duval, X., and Leport, C. (2008). Prophylaxis of infective endocarditis: current tendencies, continuing controversies. Lancet. Infect. Dis. 8, 225-232. Elliott, V., Morgan, S., Day, S., Mollerup, L.S., and Wang, W. (2001). Parental health beliefs and compliance with prophylactic penicillin administration in children with sickle cell disease. J. Pediatr. Hematol. Oncol. 23, 112-116. Erickson, P.R., and Herzberg, M.C. (1990). Purification and partial characterization of a 65-kDa platelet aggregation-associated protein antigen from the surface of Streptococcus sanguis. J. Biol. Chem. 265, 14080-14087. Ferres, H., and Nunn, B. (1983). Penicillin metabolites and platelet function. Lancet 2, 226-227. Fitzgerald, J.R., Foster, T.J., and Cox, D. (2006). The interaction of bacterial pathogens with platelets. Nat. Rev. Microbiol. 4, 445-457. Frisk, A.R., and Tunevall, G. (1972). Effect of oxyphenbutazone on concentration of penicillin in serum. Experientia 28, 296-297. Guillaumont, M., Sann, L., Leclercq, M., Dostalova, L., Vignal, B., and Frederich, A. (1993). Changes in hepatic vitamin K1 levels after prophylactic administration to the newborn. J. Pediatr. Gastroenterol. Nutr. 16, 10-14. Guze, P.A., Kalmanson, G.M., Freedman, L.R., Ishida, K., and Guze, L.B. (1983). Antibiotic prophylaxis against streptomycin-resistant and -susceptible Streptococcus faecalis endocarditis in rabbits. Antimicrob. Agents. Chemother. 24, 514-517. Hall, G., Hedstrom, S.A., Heimdahl, A., and Nord, C.E. (1993). Prophylactic administration of penicillins for endocarditis does not reduce the incidence of postextraction bacteremia. Clin. Infect. Dis. 17, 188-194. Hamada, S., and Slade, H.D. (1980). Biology, immunology, and cariogenicity of Streptococcus mutans. Microbiol. Rev. 44, 331-384. Hand, W.L., and Kingthompson, N.L. (1986). Contrasts between phagocyte antibiotic uptake and subsequent intracellular bactericidal activity. Antimicrob. Agents. Chemother. 29, 135-140. Harrison, J.L., Hoen, B., and Prendergast, B.D. (2008). Antibiotic prophylaxis for infective endocarditis. Lancet 371, 1317-1319. Hoppensteadt, D.A., Haas, S., Breddin, H.K., and Fareed, J. (1993). Modulation of laboratory parameters after therapeutic and prophylactic administration of Sandoparin. Semin. Thromb. Hemost. 19 Suppl 1, 31-35. Ito, H.O. (2006). Infective endocarditis and dental procedures: evidence, pathogenesis, and prevention. J. Med. Invest. 53, 189-198. Joos, R.W., and Hall, W.H. (1969). Determination of binding constants of serum albumin for penicillin. J. Pharmacol. Exp. Ther. 166, 113-118. Kattwinkel, J., Bloom, B.T., Delmore, P., Davis, C.L., Farrell, E., Friss, H., Jung, A.L., King, K., and Mueller, D. (1993). Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics 92, 90-98. Keettel, W.C., Scott, J.W., and Plass, E.D. (1949). An evaluation of prophylactic penicillin administration to parturient women. Am. J. Obstet. Gynecol. 58, 335-344. Khan, I.A., and Ijaz, N. (2009). Prophylaxis of infective endocarditis: current perspectives. Int. J. Cardiol. 134, e105-106. Krauwinkel, W.J., and Volkers-Kamermans, N.J. (1996). Determination of penicillin-V in human plasma by high-performance liquid chromatography and solid-phase extraction. J. Chromatogr. B Biomed. Appl. 679, 129-135. Mayer-Scholl, A., Averhoff, P., and Zychlinsky, A. (2004). How do neutrophils and pathogens interact? Curr. Opin. Microbiol. 7, 62-66. Michelson, A.D. (2010). Antiplatelet therapies for the treatment of cardiovascular disease. Nat. Rev. Drug Discov. 9, 154-169. Moreillon, P., and Que, Y.A. (2004). Infective endocarditis. Lancet 363, 139-149. Osterlind, G. (1950). The value of prophylactic systemic administration of penicillin and sulphadital in the treatment of perforating lesions of the eye. Acta. Ophthalmol. (Copenh) 28, 489-498. Pallasch, T.J., and Slots, J. (1996). Antibiotic prophylaxis and the medically compromised patient. Periodontol 2000 10, 107-138. Pastakia, K.B., Terle, D., and Prodouz, K.N. (1993). Penicillin inhibits agonist-induced expression of platelet surface membrane glycoproteins. Ann. N. Y. Acad. Sci. 677, 437-439. Pietrocola, G., Schubert, A., Visai, L., Torti, M., Fitzgerald, J.R., Foster, T.J., Reinscheid, D.J., and Speziale, P. (2005). FbsA, a fibrinogen-binding protein from Streptococcus agalactiae, mediates platelet aggregation. Blood 105, 1052-1059. Plummer, C., Wu, H., Kerrigan, S.W., Meade, G., Cox, D., and Ian Douglas, C.W. (2005). A serine-rich glycoprotein of Streptococcus sanguis mediates adhesion to platelets via GPIb. Br. J. Haematol. 129, 101-109. Prokesch, R.C., and Hand, W.L. (1982). Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob. Agents. Chemother. 21, 373-380. Que, Y.A., and Moreillon, P. (2011). Infective endocarditis. Nat. Rev. Cardiol. 8, 322-326. Rolinson, G.N., and Sutherland, R. (1965). The binding of antibiotics to serum proteins. Br. J. Pharmacol. Chemother. 25, 638-650. Sachs, B., Al Masaoudi, T., Merk, H.F., and Erdmann, S. (2004). Combined in vivo and in vitro approach for the characterization of penicillin-specific polyclonal lymphocyte reactivity: tolerance tests with safe penicillins instead of challenge with culprit drugs. Br. J. Dermatol. 151, 809-816. Schulz, C., von Beckerath, O., Okrojek, R., von Beckerath, N., and Massberg, S. (2010). Platelet dysfunction and inhibition of multiple electrode platelet aggregometry caused by penicillin. Thromb. J. 8, 13. Semple, J.W., and Freedman, J. (2010). Platelets and innate immunity. Cell. Mol. Life Sci. 67, 499-511. Shattil, S.J., Bennett, J.S., McDonough, M., and Turnbull, J. (1980). Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J. Clin. Invest. 65, 329-337. Sloand, E.M., Klein, H.G., Pastakia, K.B., Pierce, P., and Prodouz, K.N. (1992). Effect of albumin on the inhibition of platelet aggregation by beta-lactam antibiotics. Blood 79, 2022-2027. Sullam, P.M., Jarvis, G.A., and Valone, F.H. (1988). Role of immunoglobulin G in platelet aggregation by viridans group streptococci. Infect. Immun. 56, 2907-2911. Tagawa, M., Okano, S., Hayashi, Y., and Kusano, K. (1993). Prophylactic effect of milbemycin oxime against Dirofilaria immitis infection in dogs: optimum dose and administration time. J. Vet. Med. Sci. 55, 693-694. Tomas Carmona, I., Diz Dios, P., and Scully, C. (2007). Efficacy of antibiotic prophylactic regimens for the prevention of bacterial endocarditis of oral origin. J. Dent. Res. 86, 1142-1159. Triplett, D.A. (2000). Coagulation and bleeding disorders: review and update. Clin. Chem. 46, 1260-1269. Weyrich, A.S., and Zimmerman, G.A. (2004). Platelets: signaling cells in the immune continuum. Trends. Immunol. 25, 489-495. Wheat, L.J., Smith, J.W., Reynolds, J., Bemis, A.T., Treger, T., and Norton, J.A. (1988). Comparison of cefazolin, cefamandole, vancomycin, and LY146032 for prophylaxis of experimental Staphylococcus epidermidis endocarditis. Antimicrob. Agents. Chemother. 32, 63-67. Wilkins, J.N., Ashofteh, A., Setoda, D., Wheatley, W.S., Huigen, H., and Ling, W. (1997). Ultrafiltration using the Amicon MPS-1 for assessing methadone plasma protein binding. Ther. Drug Monit. 19, 83-87. Wilson, W., Taubert, K.A., Gewitz, M., Lockhart, P.B., Baddour, L.M., Levison, M., Bolger, A., Cabell, C.H., Takahashi, M., Baltimore, R.S., et al. (2007). Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116, 1736-1754. Wright, A.J. (1999). The penicillins. Mayo Clin Proc 74, 290-307. Yajima, A., Takahashi, Y., and Konishi, K. (2005). Identification of platelet receptors for the Streptococcus gordonii DL1 sialic acid-binding adhesin. Microbiol. Immunol. 49, 795-800. Yeaman, M.R. (2010). Platelets in defense against bacterial pathogens. Cell. Mol. Life Sci. 67, 525-544. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34284 | - |
dc.description.abstract | 轉糖鏈球菌(Streptococcus mutans)屬於兼性厭氧革蘭氏陽性菌,存在於人體的口腔之中,當它們有機會進入血液中,形成暫時性菌血症時,便可能經由血液循環進入心臟,進而黏附於先天有缺陷的心臟瓣膜或是人工心瓣膜上,形成贅疣(vegetation),往感染性心內膜炎(infective endocarditis)發展。以往在預防感染性心內膜炎時,美國心臟協會(AHA)將 β-lactam類藥物作為首選藥物,但在本實驗室先前的研究發現,在大鼠感染性心內膜炎模式中,使用盤尼西林預防轉糖鏈球菌引起的感染性心內膜炎並不會降低菌血症的發生。另外,血小板和轉糖鏈球菌會形成凝集構造,此凝集構造在本實驗室之前研究顯示可以有助於轉糖鏈球菌抵抗全血中嗜中性球的殺菌。因此,本實驗主要探討存在血液中的血小板和嗜中性球是否和盤尼西林有交互作用,導致轉糖鏈球菌對於抗生素的術前預防有抵抗性。本實驗結果發現轉糖鏈球菌在富含血小板的血漿(PRP)和血小板貧乏的血漿(PPP)中可以提升轉糖鏈球菌對盤尼西林的最低抑菌濃度(MIC)以及最低殺菌濃度(MBC),並且,在盤尼西林殺菌能力試驗中,當低濃度的盤尼西林存在時,轉糖鏈球菌在富含血小板的血漿中的存活率比在血小板貧乏的血漿中來得高,但是當高濃度的盤尼西林存在時,轉糖鏈球菌在富含血小板的血漿中的存活率比在血小板貧乏的血漿中來得高的現象變得不明顯或是消失,而且,利用高效液相層析儀(HPLC)測定富含血小板的血漿和血小板貧乏的血漿中的游離態盤尼西林發現沒有差異,另外,盤尼西林的存在並不會影響血小板和轉糖鏈球菌形成凝集構造,在嗜中性球殺菌試驗中亦不會影響嗜中性球的殺菌能力。因此,血小板和嗜中性球對於幫助轉糖鏈球菌抵抗抗生素可能不是很主要的因子。其他可能導致轉糖鏈球菌對於抗生素術前預防有抵抗性的因素仍需進一步探討。 | zh_TW |
dc.description.abstract | Streptococcus mutans is one of the principal dental caries causative agents and an opportunistic pathogen of infective endocarditis (IE). S. mutans can enter the bloodstream through the dental procedure to induce transient bacteremia which is the early indicator of the IE. Antibiotics prophylaxis is routinely recommended at the time of dental procedures in patients deemed to be at risk of infective endocarditis. However, no clear benefit of the traditional approach for antibiotic prophylaxis has been reported. In our previous study indicated that penicillin prophylaxis did not reduce the bacteremia caused by S. mutans in the IE rat model. Therefore, the resistant mechanism of S. mutans against antibiotic killing effect was evaluated in in vitro killing assay and in vivo bacteremia rat model. In whole blood, platelets and neutrophils have the bactericidal effect. The minimum inhibitory concentration and minimum bactericidal concentration of penicillin for S. mutans in platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were higher than in medium control. In addition, S. mutans in PRP showed higher survival rates than PPP in low-dose penicillin killing assay suggested that platelets might help S. mutans escape the killing of antibiotics. But, S. mutans in PRP did not clearly showed higher survival rates than PPP in high-dose penicillin killing assay. The concentration of free-form penicillin after incubated with PRP or PPP was similar demonstrated that permeability of penicillin into platelet was not involved in this antibiotics resistant mechanism. The morphology of bacteria-platelet aggregate varied in penicillin treatment was observed in immuno-florescence staining. On the other hand, penicillin could not change the bactericidal ability of neutrophils. In conclusion, neither the platelets nor the neutrophils were involved in S. mutans resistant to penicillin prophylaxis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:01:20Z (GMT). No. of bitstreams: 1 ntu-100-R98445107-1.pdf: 2277577 bytes, checksum: d69569d85955289ce051f1c42ce2658e (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 目錄
口試委員會審定書......................................... i 誌謝.................................................... ii 中文摘要............................................... iii Abstract ............................................... iv 目錄..................................................... v 圖表目錄............................................... vii 壹、緒論..................................................1 一、轉糖鏈球菌(Streptococcus mutans)......................1 二、感染性心內膜炎(Infective endocarditis, IE)............2 三、菌血症................................................3 四、菌血症的感染指標..................................... 4 五、血小板(Platelet)......................................4 〈一〉功能............................................4 〈二〉和細菌的交互作用................................5 六、嗜中性球..............................................6 七、術前預防(Prophylaxis).................................7 八、盤尼西林和宿主的交互作用..............................9 〈一〉盤尼西林........................................9 〈二〉盤尼西林和血小板的交互作用......................9 〈三〉盤尼西林和嗜中性球的交互作用...................10 〈四〉盤尼西林引起的過敏現象.........................11 九、研究目的與實驗設計...................................11 貳、實驗材料與方法...................................... 13 一、轉糖鏈球菌的轉型作用................................ 13 二、菌血症老鼠動物模式的建立............................ 13 三、全血球計數(Complete Blood Count, CBC)................14 四、測定最低抑菌濃度(Minimum Inhibitory Concentration, MIC)和最低殺菌濃度(Minimum Bactericidal Concentration, MBC)..14 〈一〉盤尼西林.......................................14 〈二〉健大霉素.......................................14 五、抗生素殺菌能力試驗.................................. 16 〈一〉盤尼西林.......................................16 〈二〉健大霉素.......................................17 六、凝集度試驗(Aggregometry testing).....................17 七、體外人體血液模式的建立與染色.........................17 八、人類嗜中性球之分離與純化............................ 18 九、人類嗜中性球殺菌能力試驗(Neutrophil killing assay)...19 〈一〉盤尼西林.......................................19 〈二〉健大霉素.......................................20 十、利用高效液相層析儀測定盤尼西林的含量.................20 〈一〉在大鼠血液中測定盤尼西林的含量.....................20 〈二〉在富含血小板的血漿血小板貧乏的血漿中測定盤尼西林的含量.......................................................21 参、結果.................................................22 第一部分:術前預防對於大鼠菌血症模式的效用.............. 22 一、在大鼠菌血症模式中進行術前預防時血液中菌量數的變化.. 22 二、菌血症的指標─淋巴球計數與嗜中性球-淋巴球比例....... 22 三、測定盤尼西林術前預防大鼠菌血症模式中盤尼西林的血中濃度變化.......................................................24 第二部分:利用體外殺菌模式篩選出干擾抗生素效用的血液相關因子...................................................... 24 一、血小板對於抗生素的影響.............................. 24 二、盤尼西林對於血小板的影響............................ 26 三、抗生素對於嗜中性球的影響.............................27 肆、討論................................................ 28 一、在大鼠菌血症模式中進行術前預防...................... 28 二、血小板在轉糖鏈球菌對於盤尼西林的術前預防有抵抗性扮演的角色..................................................... 28 三、嗜中性球在轉糖鏈球菌對於盤尼西林的術前預防有抵抗性扮演的角色.....................................................32 伍、參考文獻............................................ 34 圖表目錄 表一、盤尼西林對於轉糖鏈球菌在BHI、富含血小板的血漿和血小板貧乏的血漿中之最低抑菌濃度和最低殺菌濃度.................43 表二、健大霉素對於轉糖鏈球菌在BHI、富含血小板的血漿和血小板貧乏的血漿 中之最低抑菌濃度和最低殺菌濃度...............43 表三、盤尼西林對於轉糖鏈球菌在 RPMI之最低抑菌濃度和最低殺菌濃度.....................................................43 表四、健大霉素對於轉糖鏈球菌在 RPMI之最低抑菌濃度和最低殺菌濃度.....................................................43 圖一、在大鼠菌血症模式中施打不同劑量盤尼西林和健大霉素血液中菌量數的變化.............................................44 圖二、施打不同劑量盤尼西林之大鼠不同時間點血液中之淋巴球計數.......................................................45 圖三、施打不同劑量健大霉素之大鼠不同時間點血液中之淋巴球計數.......................................................46 圖四、施打不同劑量盤尼西林之大鼠不同時間點血液中之嗜中性球-淋巴球比例...............................................47 圖五、施打不同劑量健大霉素之大鼠不同時間點血液中之嗜中性球-淋巴球比例...............................................48 圖六、在大鼠血液中測定盤尼西林的含量.....................49 圖七、低濃度的盤尼西林在BHI、富含血小板的血漿和血小板貧乏的血漿中的殺菌試驗.........................................50 圖八、高濃度的盤尼西林在 BHI、富含血小板的血漿和血小板貧乏的血漿中的殺菌試驗.........................................51 圖九、以高效液相層析儀測定富含血小板的血漿和血小板貧乏的血漿中盤尼西林的含量.........................................52 圖十、10 μg/ml 的健大霉素在 BHI、富含血小板的血漿和血小板貧乏的血漿中的殺菌試驗.....................................53 圖十一、不同濃度的盤尼西林對於血小板凝集能力的影響.......54 圖十二、以共軛焦顯微鏡觀察轉糖鏈球菌和血小板形成的凝集構造在有無盤尼西林存在下的型態.................................55 圖十三、盤尼西林對於人類嗜中性球殺菌能力試驗的影響.......56 圖十四、健大霉素對於人類嗜中性球殺菌能力試驗的影響.......57 | |
dc.language.iso | zh-TW | |
dc.title | 轉糖鏈球菌對於抗生素預防感染性心內膜炎的抵抗性 | zh_TW |
dc.title | Resistance of Antibiotic Prophylaxis by Streptococcus mutans in Infective Endocarditis | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王萬波,董馨蓮,林君榮 | |
dc.subject.keyword | 轉糖鏈球菌,抗生素,感染性心內膜炎, | zh_TW |
dc.subject.keyword | Streptococcus mutans,Antibiotic,Infective endocarditis, | en |
dc.relation.page | 57 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 2.22 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。